Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Novel Insights from Clinical Practice

IL-2-Inducible T-Cell Kinase Deficiency with Pulmonary Manifestations due to Disseminated Epstein-Barr Virus Infection

Mansouri D.b · Mahdaviani S.A.a, b · Khalilzadeh S.a · Mohajerani S.A.b · Hasanzad M.a · Sadr S.a · Nadji S.A.c · Karimi S.a · Droodinia A.a · Rezaei N.d · Linka R.M.e · Bienemann K.e · Borkhardt A.e · Masjedi M.R.b · Velayati A.A.a

Author affiliations

aPediatrics Respiratory Disease Research Center, bDepartment of Clinical Immunology, and cVirology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, and dResearch Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran; eDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Centre for Child and Adolescent Health, Heinrich Heine University, Düsseldorf, Germany

Related Articles for ""

Int Arch Allergy Immunol 2012;158:418–422

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: June 29, 2011
Accepted: September 21, 2011
Published online: April 05, 2012
Issue release date: June 2012

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 2

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

IL-2-inducible T-cell kinase (ITK) deficiency is a rare inherited immunodeficiency disease characterized by homozygous mutations in the ITK gene and the inability to control Epstein-Barr virus (EBV) infection leading to EBV-associated lymphoproliferative disorders of B cell origin. Many aspects of its clinical presentation and immunologic phenotype are still unclear to clinicians. We report on a 14-year-old female patient with complaints of an 8-month history of cough and fever. Imaging studies revealed diffuse pulmonary nodules and mediastinal lymphadenopathy. Transbronchial lung biopsy showed nonmalignant polyclonal B cell proliferation. High titers of EBV DNA were detected by PCR analysis in bronchoalveolar lavage fluid, bone marrow, and blood. Genomic analysis revealed a homozygous single base pair deletion in exon 5 of the ITK gene (c.468delT) in this patient. Treatment with rituximab (anti-CD20 mab) resulted in complete clinical remission with resolution of pulmonary lesions and a negative EBV titer in serum. All patients with EBV-associated lymphoproliferative disorders should be analyzed for mutations in ITK.

© 2012 S. Karger AG, Basel


References

  1. Grasis JA, Guimond DM, Cam NR, Herman K, Magotti P, Lambris JD, Tsoukas CD: In vivo significance of ITK-SLP-76 interaction in cytokine production. Mol Cell Biol 2010;30:3596–3609.
  2. Qi Q, August A: The Tec family kinase Itk exists as a folded monomer in vivo. J Biol Chem 2009;284:29882–29892.
  3. Felices M, Berg LJ: The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J Immunol 2008;180:3007–3018.
  4. Prince AL, Yin CC, Enos ME, Felices M, Berg LJ: The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development. Immunol Rev 2009;228:115–131.
  5. Huck K, Feyen O, Niehues T, Rüschendorf F, Hübner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A: Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009;119:1350–1358.
  6. Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A, Resnick IB: IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 2011;96:472–476.
    External Resources
  7. Filipovich AH, Zhang K, Snow AL, Marsh RA: X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood 2010;116:3398–3408.
  8. Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE: X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011;152:13–30.
  9. Rigaud S, Fondanèche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint Basile G, Latour S: XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006;444:110–114.
  10. Tabarsi P, Moradi A, Marjani M, Baghaei P, Hashemian SM, Nadji SA, Fakharian A, Mansouri D, Masjedi M, Velayati A: Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. Ann Thorac Med 2011;6:91–95.
    External Resources
  11. Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF: Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2011, E-pub ahead of print.
  12. Gadue P, Stein PL: NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. J Immunol 2002;169:2397–2406.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: June 29, 2011
Accepted: September 21, 2011
Published online: April 05, 2012
Issue release date: June 2012

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 2

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.